Autosomal dominant polycystic kidney disease rates in the Military Health System are comparable to the general population, ...

Lupin receives USFDA approval for its generic version of Tolvaptan tablets, indicated for autosomal dominant polycystic ...

Tolvaptan is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic ...

The drug, a copy of Jynarque, could add up to $200 million in annual revenue by FY26, strengthening Lupin’s foothold in ...

Before receiving a kidney transplant, patients with autosomal dominant polycystic kidney disease often undergo a nephrectomy. But there hasn’t been clear guidance on who’s a good candidate ...

Lupin gains US FDA approval for Tolvaptan tablets in various dosages, marking a significant entry into the nephrology market.

Mumbai: Global pharma major, Lupin Limited, has received approval from the United States Food and Drug Administration (U.S.

The approval includes multiple strengths: 15mg, 30mg, 45mg, 60mg, and 90mg, allowing for flexible dosing options.

Pharma major Lupin Ltd on Thursday said it has received approval from the US health regulator for its generic version of ...

Global pharma major Lupin Limited (Lupin) announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application for tolvaptan ...

Lupin receives FDA approval for Tolvaptan tablets, launching soon with exclusive generic drug exclusivity for 180 days.

Regulus Therapeutics Inc.’s RGLS share price has surged by 7.85%, which has investors questioning if this is right time to ...